U.S. Colorectal Cancer Screening Market Size, Trends, and Growth Forecast

Market Size and Overview

U.S. colorectal cancer screening market size was valued at US$ 6.41 Bn in 2025 and is expected to reach US$ 10.77 Bn by 2032, grow at a compound annual growth rate (CAGR) of 7.7% from 2025 to 2032.

 This robust market growth is supported by a surge in colonoscopy and non-invasive screening tests such as fecal immunochemical tests (FIT). The increasing prevalence of colorectal cancer within the aging U.S. population and evolving screening guidelines further reinforce the expanding U.S. Colorectal Cancer Screening Market Scope and revenue potential. Recent market insights underline steady growth aligned with advancements in screening accuracy and patient adherence.

Market Drivers

One of the primary market drivers is the escalating incidence of colorectal cancer coupled with an emphasis on early detection. According to the National Cancer Institute’s 2025 report, new colorectal cancer cases in the U.S. showed a 3% year-over-year rise, particularly among individuals aged 50 and above. This has accelerated demand for reliable screening technologies, encouraging healthcare providers to invest in comprehensive screening programs.

For instance, the increased adoption of stool DNA tests and blood-based biomarker screenings in 2024-2025 has broadened access, fueling market growth and underpinning new market opportunities. These market dynamics demonstrate the industry's responsiveness to rising disease burden and preventive healthcare trends.

PEST Analysis

- Political: The U.S. government’s reinforced healthcare policies in 2025, including expanded Medicare and Medicaid coverage for colon cancer screening, are positively impacting market revenue and accessibility. Legislative initiatives driving reimbursement for newer, less invasive procedures are enabling higher adoption rates by healthcare providers.

- Economic: Rising healthcare expenditure in 2024, focused on cancer prevention and early diagnosis, is bolstering market growth strategies. Stable healthcare funding amid inflation concerns supports sustained investments in diagnostic infrastructure and R&D within market segments.

- Social: Growing public awareness and changing demographics, especially the rising geriatric population, have influenced industry size expansion. Campaigns promoting colorectal cancer awareness in 2025 have improved screening compliance, addressing market challenges related to patient reluctance and screening hesitancy.

- Technological: Advances in screening technologies such as next-generation sequencing for stool DNA tests introduced in late 2024 and AI-assisted colonoscopy systems in 2025 are revolutionizing market trends. These innovations enhance diagnostic accuracy and reduce procedural discomfort, thereby expanding the market scope and competitive differentiation among market players.

Promotion and Marketing Initiative

A key marketing initiative observed in 2025 involved a nationwide awareness campaign launched by a leading colorectal cancer advocacy organization, integrating digital platforms and physician outreach programs. This campaign employed social media, patient testimonials, and interactive webinars, resulting in a 15% increase in screening appointments across several states. Such targeted promotion efforts are essential in addressing market restraints like low screening uptake and improving business growth for market companies by aligning marketing strategies with evolving patient preferences and technological acceptance.

Key Players

- Polymedco Inc.
- Eiken Chemical Co. Ltd.
- Sysmex Corporation
- Quidel Corporation
- Novigenix SA
- Banner Health
- Exact Sciences Corporation
- Quest Diagnostics
- Abbott Laboratories
- Roche Diagnostics
- Hologic Inc.
- F. Hoffmann-La Roche AG

Recent strategies in 2024 and 2025 by these players include:

- Polymedco Inc. expanded its portfolio with liquid biopsy screening tests, enhancing market share and penetrating underserved segments.
- Novigenix SA secured partnerships with major healthcare providers to introduce advanced biomarker-based tests, positively impacting their market revenue.
- Sysmex Corporation deployed AI-driven analysis tools integrated into endoscopic systems, improving procedural efficiency and patient outcomes.
Collectively, these strategies exemplify market growth tactics underpinning competitive gains and respond to evolving market challenges and opportunities.

Frequently Asked Questions (FAQs)

Q1. Who are the dominant players in the U.S. colorectal cancer screening market?
A1. Dominant market players include Polymedco Inc., Eiken Chemical Co. Ltd., Sysmex Corporation, Quidel Corporation, and Novigenix SA, known for their innovative screening technologies and extensive collaborations within the U.S. healthcare ecosystem.

Q2. What will be the size of the U.S. colorectal cancer screening market in the coming years?
A2. The market size is projected to grow from USD 6.41 billion in 2026 to USD 10.77 billion by 2032, reflecting a CAGR of 8.0%, driven by rising cancer incidence and advancements in screening technologies.

Q3. Which end-user industry has the largest growth opportunity in the U.S. colorectal cancer screening market?
A3. The healthcare provider segment, including hospitals and diagnostic labs, presents the largest growth opportunity due to increased screening programs and technology adoption throughout 2024 and 2025.

Q4. How will market development trends evolve over the next five years?
A4. Market trends indicate a shift towards minimally invasive, AI-enhanced, and molecular diagnostic-based colorectal cancer screening methods, enhancing detection rates and patient comfort, alongside increasing integration of digital health platforms by 2032.

Q5. What is the nature of the competitive landscape and challenges in the U.S. colorectal cancer screening market?
A5. The competitive landscape involves extensive product innovation and strategic partnerships, with challenges including market restraints such as patient reluctance, high procedural costs, and regulatory hurdles impacting screening frequency.

Q6. What go-to-market strategies are commonly adopted in the U.S. colorectal cancer screening market?
A6. Market companies commonly adopt strategies like expanding product portfolios, collaborating with healthcare providers, launching awareness campaigns, and utilizing digital marketing tools to enhance patient engagement and screening uptake.

‣ Get more insights on :  U.S. Colorectal Cancer Screening Market

‣ Get this Report in Japanese Language:  米国大腸がん検査市場

‣ Get this Report in Korean Language:  미국대장암검진시장

‣ Read More Related Articles:  Patient Risk Stratification: Managing Healthcare More Efficiently

Author Bio:

Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.